Felis ISSN 2398-2950

Cefovecin

Synonym(s): Convenia

Contributor(s): Carrie Passmore

Introduction

Name

  • Cefovecin.

Class of drug

  • Third generation cephalosporin antimicrobial.

Description

Chemical name

  • (6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[(2S)-tetrahydro-2-furanyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, monosodium salt.

Molecular formula

  • C17H18N5NaO6S2

Molecular weight

  • 475.47

Physical properties

  • The powder is off-white to yellow and the diluent is a clear, colorless liquid.
  • Each vial of lyophilized powder contains 852 mg Cefovecin (as sodium salt), containing methylparahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) as excipients.
  • In Europe lyophilized powder has to be reconstituted with a specific diluent containing 13 mg/ml benzyl alcohol and 10.8 ml water for injections, yielding an 80.0 mg/ml solution of Cefovecin.
  • In common with other cephalosporin antibiotics, the color of the solution darkens over time. Potency is not affected when the solution is stored as described.

Storage requirements

  • Store powder and the reconstituted product in original carton, refrigerated at 2-8°C (32-46°F). Use entire contents of the vial within 28 days of reconstitution.
  • Protect from light.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

Indications vary between Europe and USA and other continents (check local package insert).

EU indications

  • For the treatment of skin and soft abscesses   Abscess  and wounds associated withPasteurella multocida,Fusobacteriumspp,Bacteriodes spp,Prevotella oralis, ²-hemolyticStreptococciand/orStaphylococcus intermedius.
  • For the treatment of urinary tract infections   Cystitis: bacterial  associated withEscherichia coli.

US indications

  • Treatment of skin infections (wounds and abscesses) caused by susceptible strains ofPasteurella multicida.
  • For the treatment of urinary tract infections associated withEscherichia coli.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

  • Concurrent use of other substances that have a high degree of protein binding (eg furosemide, ketoconazole, or non-steroidal anti-inflammatory drugs (NSAIDs)) may compete with cefovecin binding and thus may cause adverse effects. 

with diagnostic tests

  • No known or anticipated interactions with diagnostic tests, but specific evaluations have not been performed.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references fromPubMed.
  • Six Ret al(2009)Effectiveness of cefovecin sodium for the treatment of cats with abscesses and infected wounds.JAVMA234, 81-87PubMed
  • Passmore C A, Sherington J, Stegemann M R (2008)Efficacy and safety of Cefovecin (Convenia") for the treatment of urinary tract infections in cats.  JSAP 49(6), 295PubMed.  
  • Stegemann M R, Sherington J, Passmore C A (2007)The efficacy and safety of Cefovecin (Convenia") in the treatment of feline abscesses and infected wounds.JSAP 48(12),  683-689PubMed.
  • Stegemann M R, Passmore C A, Sherington J, Lindeman C J, Papp G, Weigel D J, Skogerboe T L (2006)Antimicrobial activity and spectrum of cefovecin, a new extended- spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America.Antimicrob Agents Chemother50(7), 2286-2292PubMed.

Other sources of information


ADDED